DUBLIN–(BUSINESS WIRE)–The “Global
Lung Cancer Drugs Market – Drivers, Restraints, Opportunities, Trends,
and Forecast up to 2025” report has been added to ResearchAndMarkets.com’s
The Global Lung Cancer Drugs Market will grow at a CAGR of 13.6% during
the forecast period.
The market has witnessed steady growth in the past few years with the
introduction of novel products, which have augmented the acceptance of
immunotherapy drugs in the market. The market is fueled by upsurge in
the incidence of lung cancer cases across the globe – owing to
increasing diagnosis rate and mainly due to increasing tobacco
consumption, increase in the lung cancer treatment rates, increasing
rate of effective drug approvals as first-line therapies, strategic
deals to develop new products, increasing R&D spending, and rapid
industrialization leading to increased pollution.
The leading global pharmaceutical companies are focusing on product
approvals as first-line treatment therapy and combination treatment with
chemotherapy, collaborations, and regulatory submission of already
matured cancer treatments in the developing countries as a major
strategy to increase their revenue. Many of the global players are also
focusing on providing home infusion services in the developed markets
with secured and safe cold chain logistic infrastructure. This
Direct-to-Patient (DTP) strategy is also helping market players to
expand their patient volumes and thus the overall revenues globally.
The market generates the revenue from the key players operating in this
field and some of them include, F. Hoffmann-La Roche Ltd, Bristol-Myers
Squibb, Janssen, Amgen, AstraZeneca PLC, Pfizer, Inc., Eli Lilly &
Company Ltd, and Novartis AG.
According to analysis, North America accounted for the largest share of
the global lung cancer drugs market in 2018 and will retain a high
position during the forecast period 2019-2025. According to WHO, cancer
accounted for an estimated 9.6 million deaths in 2018 and the most
common cancer among all types is lung cancer (2.09 million cases). An
estimated 234,030 new cases of lung cancer were diagnosed in 2018,
representing about 13% of all cancer diagnoses in the country.
Europe is the second major shareholder of the global lung cancer drugs
market. There were an estimated 3.91 million new cases of cancer and
1.93 million deaths from cancer in 2018. Lung cancer is the third most
common cancer type of cancer (470,000) after the female breast cancer
and colorectal cancer (500,000). In the UK, around 46,700 new lung
cancer cases are recorded annually and it is the third most common
cancer. The Asia Pacific is expected to grow at high double digit CAGR
during the forecast period, owing to factors such as the increasing
prevalence of cancer cases, growing healthcare expenditure, and
increased healthcare awareness.
By Disease Type:
- Small cell lung cancer (SCLC)
- Non-small cell lung cancer (NSCLC)
The non-small cell lung cancer segment occupied the largest share in
2018 and is expected to grow at mid-double digit CAGR during the
forecast period. The increasing incidence and prevalence of non-small
cell lung cancer and rapid industrialization make the segment the
fastest growing during the forecast period 2019-2025.
By Molecule Type:
- Small molecules
In 2018, the small molecules segment occupied the largest share and
biologics is expected to grow at a high CAGR during the forecast period
due to increasing adoption of biologics, strong pipeline targeting
first-line treatments, and recent product approvals.
- North America
North America is dominant in the global lung cancer drugs market
followed by Europe and Asia Pacific. The significant share of the North
America market comes from the US due to the availability of favourable
The global lung cancer drugs market has massive growth opportunities in
both developed and developing regions. Many companies are concentrating
on new approvals, collaborations, and development of new drugs to treat
lung cancer due to an increase in the incidence of cancer and the need
for advanced treatments.
For instance, the European Commission has approved brigatinib (Alunbrig)
developed by Takeda Pharmaceutical in November 2018 to treat adult
patients with ALK-positive non-small cell lung cancer (NSCLC) who were
previously treated with crizotinib (Xalkori). FDA approved durvalumab
(Imfinzi) developed by AstraZeneca Inc. in February 2018 for the
treatment of unresectable stage III non-small cell lung cancer whose
disease has not progressed following concurrent platinum-based
chemotherapy and radiation therapy.
In addition, other leading vendors are focusing on investing huge on
research and development activities to develop new products to obtain a
high share in the market.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- Bristol-Myers Squibb
- Pfizer Inc.
- Eli Lilly and Company Ltd.
- Novartis AG
Key Competitive Facts
Increasing incidence of the disease globally, promising drug pipeline,
and enormous R&D activities for lung cancer drug development are the
major factors driving the market growth.
The pipeline of oncology drugs in the clinical development has
expanded by 45% over the past 10 years; 87% of the late-stage pipeline
is targeted therapies, which include small molecule protein kinase
inhibitors and biologic monoclonal antibodies.
Understanding the potential market opportunity with precise market
size and forecast data.
A detailed market analysis focusing on the growth of lung cancer drugs
- Factors influencing the growth of the lung cancer drugs market.
- In-depth competitive analysis of dominant and pure-play vendors.
Prediction analysis of the lung cancer drugs market in both developed
and developing regions.
- Key insights related to major segments of the lung cancer drugs market.
Latest market trend analysis impacting the buying behaviour of the
1 Industry Outlook
1.1 Industry Overview
1.1.1 Top Pharma Drugs by Sales ($Million)
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition
3.2 Segmented Addressable Market (SAM)
3.3 Trends of the Lung Cancer Drugs Market
3.4 Related Markets
3.4.1 Over-the-Counter (OTC) Drugs
3.4.2 Respiratory Drugs
3.4.3 Diabetes Drugs
4 Market Outlook
4.1 Oncology Drugs Approved by FDA (2014-2018)
4.2 Market Segmentation
4.3 PEST Analysis
4.4 Porter 5 (Five) Forces
5 Market Characteristics
5.1 DRO – Global Lung Cancer Drugs Market Dynamics
220.127.116.11 Increasing incidence of lung cancer cases across the globe
18.104.22.168 Recent drug approvals and collaborations to develop new products
22.214.171.124 Increasing R&D spending for the development of new products
126.96.36.199 Rapid industrialization leading to increasing pollution
188.8.131.52 High treatment cost
184.108.40.206 Patent loss of key drugs to slow down the pace of the market
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Disease Types: Market Size and Analysis
6.2 Small Cell Lung Cancer (SCLC)
6.3 Non-Small Cell Lung Cancer (NSCLC)
7 Molecule Type: Market Size and Analysis
7.2 Small Molecules
8 Regions: Market Size and Analysis
8.2 North America
8.4 Asia Pacific
8.5 Rest of the World
9 Competitive Landscape
10 Vendor Profiles
10.1 F. Hoffmann-La Roche Ltd.
10.1.2 Business Units
10.1.3 Geographic Revenue
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategies
10.2 AstraZeneca PLC
10.3 Pfizer Inc.
10.4 Eli Lilly & Company Ltd.
10.5 Novartis AG
11 Companies to Watch For
11.1 Bristol-Myers Squibb
11.2 GlaxoSmithKline PLC
11.3 Merck & Co. Inc.
11.4 Sanofi S.A.
11.5 Celgene Corporation
For more information about this report visit https://www.researchandmarkets.com/r/35ymcy
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900